A Phase 1/2a Study of BMS-986242 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1) in Advanced Malignant Tumors
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs BMS-986242 (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 19 Sep 2019 Status changed from completed to discontinued.
- 26 Jul 2019 Status changed to completed.
- 26 Sep 2018 Status changed from active, no longer recruiting to discontinued.